Table 3. Combined discovery and replication analysis: site-specific and combined risk estimates for serous ovarian cancer for TERT rs7726159 among non-Hispanic whites.

			Heterozygotes			Homozygotes			Per-allele
Study	Controls	Serous Cases	aOR	(95% CI)	P	aOR	(95% CI)	P	aOR	(95% CI)	P
SEA	1,213	383	1.35	(1.05–1.73)	0.019	1.65	(1.14–2.38)	0.008	1.30	(1.10–1.54)	0.003
AUS	1,202	636	1.30	(1.06–1.60)	0.012	1.27	(0.92–1.76)	0.148	1.18	(1.02–1.37)	0.025
MAL	764	264	1.50	(1.10–2.03)	0.009	1.37	(0.86–2.19)	0.184	1.27	(1.03–1.57)	0.025
UKO	564	235	0.95	(0.68–1.32)	0.754	0.89	(0.50–1.59)	0.685	0.95	(0.74–1.21)	0.658
USC	218	128	0.71	(0.45–1.13)	0.152	0.53	(0.24–1.15)	0.108	0.72	(0.51–1.01)	0.056
MAY	61	125	1.53	(0.80–2.94)	0.198	0.80	(0.26–2.40)	0.684	1.09	(0.67–1.78)	0.732
Combined (all studies)	4,022	1,771	1.23	(1.09–1.39)	0.001	1.19	(0.98–1.44)	0.072	1.14	(1.04–1.24)	0.003

^aEstimates are adjusted for age (at interview in controls, at diagnosis in cases) and additionally for study site in combined (all studies) estimates.